Literature DB >> 30464153

Statin Intolerance and Suboptimal Statin Therapy.

Hayato Tada1, Masa-Aki Kawashiri1.   

Abstract

Entities:  

Keywords:  Dyslipidemia; Optimal medical therapy; Statin; Statin intolerance

Mesh：

Substances：

Year:  2018        PMID： 30464153      PMCID： PMC6514179          DOI： 10.5551/jat.ED106

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN： 1340-3478            Impact factor:   4.928


× No keyword cloud information.
  9 in total

1.  ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins.

Authors:  Richard C Pasternak; Sidney C Smith; C Noel Bairey-Merz; Scott M Grundy; James I Cleeman; Claude Lenfant
Journal:  Circulation       Date:  2002-08-20       Impact factor: 29.690

2.  Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study.

Authors:  Hiroshi Mabuchi; Atsushi Nohara; Junji Kobayashi; Masa-aki Kawashiri; Shoji Katsuda; Akihiro Inazu; Junji Koizumi
Journal:  Atherosclerosis       Date:  2007-08-06       Impact factor: 5.162

Review 3.  The Role of Nutraceuticals in Statin Intolerant Patients.

Authors:  Maciej Banach; Angelo Maria Patti; Rosaria Vincenza Giglio; Arrigo F G Cicero; Atanas G Atanasov; Gani Bajraktari; Eric Bruckert; Olivier Descamps; Dragan M Djuric; Marat Ezhov; Zlatko Fras; Stephan von Haehling; Niki Katsiki; Michel Langlois; Gustavs Latkovskis; G B John Mancini; Dimitri P Mikhailidis; Olena Mitchenko; Patrick M Moriarty; Paul Muntner; Dragana Nikolic; Demosthenes B Panagiotakos; Gyorgy Paragh; Bernhard Paulweber; Daniel Pella; Christos Pitsavos; Željko Reiner; Giuseppe M C Rosano; Robert S Rosenson; Jacek Rysz; Amirhossein Sahebkar; Maria-Corina Serban; Dragos Vinereanu; Michal Vrablík; Gerald F Watts; Nathan D Wong; Manfredi Rizzo
Journal:  J Am Coll Cardiol       Date:  2018-07-03       Impact factor: 24.094

4.  Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.

Authors:  Ajay Gupta; David Thompson; Andrew Whitehouse; Tim Collier; Bjorn Dahlof; Neil Poulter; Rory Collins; Peter Sever
Journal:  Lancet       Date:  2017-05-02       Impact factor: 79.321

5.  Therapeutic effects of ML-236B in primary hypercholesterolemia.

Authors:  A Yamamoto; H Sudo; A Endo
Journal:  Atherosclerosis       Date:  1980-03       Impact factor: 5.162

6.  SLCO1B1 variants and statin-induced myopathy--a genomewide study.

Authors:  E Link; S Parish; J Armitage; L Bowman; S Heath; F Matsuda; I Gut; M Lathrop; R Collins
Journal:  N Engl J Med       Date:  2008-07-23       Impact factor: 91.245

7.  Lipid Management in a Japanese Community:Attainment Rate of Target Set by the Japan Atherosclerosis Society Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases 2012.

Authors:  Hayato Tada; Masa-Aki Kawashiri; Atsushi Nohara; Akihiro Inazu; Junji Kobayashi; Kenji Yasuda; Hiroshi Mabuchi; Masakazu Yamagishi; Kenshi Hayashi
Journal:  J Atheroscler Thromb       Date:  2016-08-29       Impact factor: 4.928

Review 8.  Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials.

Authors:  Hua Qu; Ming Guo; Hua Chai; Wen-Ting Wang; Zhu-Ye Gao; Da-Zhuo Shi
Journal:  J Am Heart Assoc       Date:  2018-10-02       Impact factor: 5.501

9.  Real-World Data to Identify Hypercholesterolemia Patients on Suboptimal Statin Therapy.

Authors:  Kouji Kajinami; Asuka Ozaki; Yuki Tajima; Shizuya Yamashita; Hidenori Arai; Tamio Teramoto
Journal:  J Atheroscler Thromb       Date:  2018-10-26       Impact factor: 4.928
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.